Monday 6-17-2014 Amgen Inc (AMGN) $AMGN opened at 116.75 hitting the high price of 116.85 and a day low of 115.67 with a total volume of 2,219,026. AMGN had a previous close of 116.16 and has been seeing an average volume of 2,452,600.
Overall Average: 8% Buy
Recent stock forum discussions about AMGN http://investorshangout.com/search?q=AMGN&...mp;yt0=Go!
Final Glance: Biotechnology companies
AP - Tue Jun 17, 5:03PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading: (full story)
Midday Glance: Biotechnology companies
AP - Tue Jun 17, 12:27PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.: (full story)
Early Glance: Biotechnology companies
AP - Tue Jun 17, 9:39AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.: (full story)
3 Undervalued Amgen Growth Opportunities to Watch
Stephen D., Simpson,, The Motley Fool - Motley Fool - Mon Jun 16, 4:30PM CDT
Amgen hasn't put as many eggs into the megablockbuster basket as Merck or Bristol-Myers Squibb , nor has it sought to utterly dominate a therapeutic area the way Biogen Idec may dominate MS. What Amgen does offer, though, is a deep pipeline... (full story)
Amgen Joins The National Cancer Institute And Research Partners To Help Accelerate Development Of Personalized Treatment Approaches For Squamous Cell Lung Cancer
PR Newswire - Mon Jun 16, 3:03PM CDT
Amgen (NASDAQ:AMGN) announced today that it will collaborate with the National Cancer Institute (NCI), part of the National Institutes of Health, and other public and private sector partners on the Lung Master Protocol (Lung-MAP), a groundbreaking new clinical trial program that will use biomarker-driven research and genomic profiling to match squamous cell lung cancer patients to investigational treatments based on their individual cancer profiles. Lung-MAP is the first trial of its kind to study a large number of rare lung cancer subsets under one trial protocol. (full story)
Groundbreaking Collaborative Clinical Trial Launched
PR Newswire - Mon Jun 16, 8:00AM CDT
A unique public-private collaboration among the National Cancer Institute (NCI), part of the National Institutes of Health, SWOG Cancer Research, Friends of Cancer Research (Friends), the Foundation for the National Institutes of Health (FNIH), five pharmaceutical companies (Amgen, Genentech, Pfizer, AstraZeneca, and AstraZeneca's global biologics R&D arm, MedImmune), and Foundation Medicine today announced the initiation of the Lung Cancer Master Protocol (Lung-MAP) trial. (full story)
Is Gene Therapy Medicine's Next Big Thing?
Todd Campbell, The Motley Fool - Motley Fool - Sat Jun 14, 12:05PM CDT
Bluebird Bio is a small company with big ideas. The clinical stage biotechnology company is researching novel treatments that seek to insert missing genes into patient stem cells. The science behind Bluebird's approach is so compelling that ... (full story)
The Zacks Analyst Blog Highlights: China Mobile, China Petroleum and Chemical, Trina Solar, AstraZeneca and Amgen
PR Newswire - Fri Jun 13, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the China Mobile Limited (NYSE:CHL-Free Report), China Petroleum and Chemical Corp. (NYSE:SNP-Free Report), Trina Solar Limited (NYSE:TSL-Free Report), AstraZeneca (NYSE:AZN-Free Report) andAmgen (Nasdaq:AMGN-Free Report). (full story)
Is Amgen's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Thu Jun 12, 4:30PM CDT
Amgen is one of the globe's biggest drug companies, and investors looking to sprinkle growth-oriented biotechnology companies into dividend portfolios often consider buying its shares. Big drug companies such as Amgen, AbbVie , and Johnson... (full story)
Amgen-AstraZeneca Psoriatic Arthritis Drug Shows Improvement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 4:10PM CDT
AstraZeneca (AZN) and partner Amgen (AMGN) announced that data from a phase II study evaluating the use of brodalumab in patients suffering from psoriatic arthritis was published in The New England Journal of Medicine. (full story)
InterMune Up On Bullish View Of U.S. Esbriet Launch
at Investor's Business Daily - Thu Jun 12, 11:57AM CDT
Biotech InterMune (ITMN) hit a three-year high on the stock market today after UBS lifted its price target for the company on bullish expectations for a drug launch. UBS analyst Andrew Peters wrote that he expects Esbriet to become the standard of... (full story)
Expansions, New Leadership, Annual Award Winners, FDA Approvals, and Abstracts Presentations - Analyst Notes on AbbVie, Amgen, Regeneron Pharmaceuticals Inc, Valeant Pharmaceuticals and Lilly
PR Newswire - Thu Jun 12, 5:40AM CDT
Today, Analysts Review released its analysts' notes regarding AbbVie Inc. (NYSE: ABBV), Amgen, Inc. (NASDAQ: AMGN), Regeneron (NASDAQ: REGN), Valeant Pharmaceuticals Intl Inc (NYSE: VRX) and Eli Lilly and Co (NYSE: LLY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3638-100free. (full story)
Renal Cell Carcinoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5lwrwg/renal_cell) has announced the addition of the "Renal Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Renal Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Renal Cell Carcinoma and enlists all their major and minor projects Companies Mentioned: - Bristol-Myers Squibb - Boehringer Ingelheim - Kyowa Hakko Kirin - Amgen - Eli Lilly and Company - GlaxoSmithKline - Seattle Genetics - Genentech - Agenus - Merck & Co - Celltrion - Astellas Pharma - ImmunoGen - Ono - Pfizer - Taiho - Onyx - Bayer - Advaxis - Hemispherx - Celldex Therapeutics, Inc. - Active Biotech AB - Lorus Therapeutics Inc. - Lpath, Inc. - Bionomics Limited - Flamel Technologies S.A. - Mologen AG - Threshold Pharmaceuticals, Inc. - Colby Pharmaceutical Company - Wilex AG For more information visit http://www.researchandmarkets.com/research/5lwrwg/renal_cell (full story)
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j7t8xn/neuro_endocrine) has announced the addition of the "Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Neuro Endocrine (Carcinoid) Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuro Endocrine (Carcinoid) Carcinoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Neuro Endocrine (Carcinoid) Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neuro Endocrine (Carcinoid) Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Ipsen S.A. - Novartis AG - Progenics Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. - Jiangsu Hengrui Medicine Co., Ltd. - Camurus AB - Vascular Biogenics Ltd. - Advanced Accelerator Applications - Foresee Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/j7..._endocrine (full story)
Overall Average: 8% Buy
Recent stock forum discussions about AMGN http://investorshangout.com/search?q=AMGN&...mp;yt0=Go!
Final Glance: Biotechnology companies
AP - Tue Jun 17, 5:03PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading: (full story)
Midday Glance: Biotechnology companies
AP - Tue Jun 17, 12:27PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.: (full story)
Early Glance: Biotechnology companies
AP - Tue Jun 17, 9:39AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.: (full story)
3 Undervalued Amgen Growth Opportunities to Watch
Stephen D., Simpson,, The Motley Fool - Motley Fool - Mon Jun 16, 4:30PM CDT
Amgen hasn't put as many eggs into the megablockbuster basket as Merck or Bristol-Myers Squibb , nor has it sought to utterly dominate a therapeutic area the way Biogen Idec may dominate MS. What Amgen does offer, though, is a deep pipeline... (full story)
Amgen Joins The National Cancer Institute And Research Partners To Help Accelerate Development Of Personalized Treatment Approaches For Squamous Cell Lung Cancer
PR Newswire - Mon Jun 16, 3:03PM CDT
Amgen (NASDAQ:AMGN) announced today that it will collaborate with the National Cancer Institute (NCI), part of the National Institutes of Health, and other public and private sector partners on the Lung Master Protocol (Lung-MAP), a groundbreaking new clinical trial program that will use biomarker-driven research and genomic profiling to match squamous cell lung cancer patients to investigational treatments based on their individual cancer profiles. Lung-MAP is the first trial of its kind to study a large number of rare lung cancer subsets under one trial protocol. (full story)
Groundbreaking Collaborative Clinical Trial Launched
PR Newswire - Mon Jun 16, 8:00AM CDT
A unique public-private collaboration among the National Cancer Institute (NCI), part of the National Institutes of Health, SWOG Cancer Research, Friends of Cancer Research (Friends), the Foundation for the National Institutes of Health (FNIH), five pharmaceutical companies (Amgen, Genentech, Pfizer, AstraZeneca, and AstraZeneca's global biologics R&D arm, MedImmune), and Foundation Medicine today announced the initiation of the Lung Cancer Master Protocol (Lung-MAP) trial. (full story)
Is Gene Therapy Medicine's Next Big Thing?
Todd Campbell, The Motley Fool - Motley Fool - Sat Jun 14, 12:05PM CDT
Bluebird Bio is a small company with big ideas. The clinical stage biotechnology company is researching novel treatments that seek to insert missing genes into patient stem cells. The science behind Bluebird's approach is so compelling that ... (full story)
The Zacks Analyst Blog Highlights: China Mobile, China Petroleum and Chemical, Trina Solar, AstraZeneca and Amgen
PR Newswire - Fri Jun 13, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the China Mobile Limited (NYSE:CHL-Free Report), China Petroleum and Chemical Corp. (NYSE:SNP-Free Report), Trina Solar Limited (NYSE:TSL-Free Report), AstraZeneca (NYSE:AZN-Free Report) andAmgen (Nasdaq:AMGN-Free Report). (full story)
Is Amgen's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Thu Jun 12, 4:30PM CDT
Amgen is one of the globe's biggest drug companies, and investors looking to sprinkle growth-oriented biotechnology companies into dividend portfolios often consider buying its shares. Big drug companies such as Amgen, AbbVie , and Johnson... (full story)
Amgen-AstraZeneca Psoriatic Arthritis Drug Shows Improvement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 4:10PM CDT
AstraZeneca (AZN) and partner Amgen (AMGN) announced that data from a phase II study evaluating the use of brodalumab in patients suffering from psoriatic arthritis was published in The New England Journal of Medicine. (full story)
InterMune Up On Bullish View Of U.S. Esbriet Launch
at Investor's Business Daily - Thu Jun 12, 11:57AM CDT
Biotech InterMune (ITMN) hit a three-year high on the stock market today after UBS lifted its price target for the company on bullish expectations for a drug launch. UBS analyst Andrew Peters wrote that he expects Esbriet to become the standard of... (full story)
Expansions, New Leadership, Annual Award Winners, FDA Approvals, and Abstracts Presentations - Analyst Notes on AbbVie, Amgen, Regeneron Pharmaceuticals Inc, Valeant Pharmaceuticals and Lilly
PR Newswire - Thu Jun 12, 5:40AM CDT
Today, Analysts Review released its analysts' notes regarding AbbVie Inc. (NYSE: ABBV), Amgen, Inc. (NASDAQ: AMGN), Regeneron (NASDAQ: REGN), Valeant Pharmaceuticals Intl Inc (NYSE: VRX) and Eli Lilly and Co (NYSE: LLY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3638-100free. (full story)
Renal Cell Carcinoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5lwrwg/renal_cell) has announced the addition of the "Renal Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Renal Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Renal Cell Carcinoma and enlists all their major and minor projects Companies Mentioned: - Bristol-Myers Squibb - Boehringer Ingelheim - Kyowa Hakko Kirin - Amgen - Eli Lilly and Company - GlaxoSmithKline - Seattle Genetics - Genentech - Agenus - Merck & Co - Celltrion - Astellas Pharma - ImmunoGen - Ono - Pfizer - Taiho - Onyx - Bayer - Advaxis - Hemispherx - Celldex Therapeutics, Inc. - Active Biotech AB - Lorus Therapeutics Inc. - Lpath, Inc. - Bionomics Limited - Flamel Technologies S.A. - Mologen AG - Threshold Pharmaceuticals, Inc. - Colby Pharmaceutical Company - Wilex AG For more information visit http://www.researchandmarkets.com/research/5lwrwg/renal_cell (full story)
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j7t8xn/neuro_endocrine) has announced the addition of the "Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Neuro Endocrine (Carcinoid) Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuro Endocrine (Carcinoid) Carcinoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Neuro Endocrine (Carcinoid) Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neuro Endocrine (Carcinoid) Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Ipsen S.A. - Novartis AG - Progenics Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. - Jiangsu Hengrui Medicine Co., Ltd. - Camurus AB - Vascular Biogenics Ltd. - Advanced Accelerator Applications - Foresee Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/j7..._endocrine (full story)
